MaltSci 麦伴科研

Appearance

Popular Reports / Clinical Medicine

This report is written by MaltSci based on the latest literature and research findings

What are the latest treatments for obesity? ​

Abstract ​

Obesity has emerged as a critical global health challenge, with its prevalence increasing dramatically over the past few decades. Defined by the World Health Organization as a body mass index (BMI) of 30 or greater, obesity is associated with numerous comorbidities, including cardiovascular diseases, type 2 diabetes, and certain cancers, thereby significantly impacting healthcare systems and economies worldwide. Recent estimates indicate that nearly 650 million adults globally are classified as obese, underscoring the urgent need for effective therapeutic strategies. This review systematically explores the latest advancements in obesity treatment, encompassing pharmacological interventions, surgical options, lifestyle modifications, and emerging therapies. Current pharmacological treatments include FDA-approved medications such as orlistat, liraglutide, semaglutide, and tirzepatide, which primarily target appetite regulation and metabolic processes. Surgical interventions, particularly bariatric surgery, remain the gold standard for severe obesity, providing significant and sustained weight reduction. Lifestyle modifications, including dietary changes and physical activity, are fundamental components of obesity management, complemented by psychological support and behavioral therapies. Additionally, novel treatments such as gene therapy and technology-driven solutions are beginning to reshape the landscape of obesity management, presenting novel avenues for personalized medicine. The implications of these treatments extend beyond individual health, significantly impacting public health resources and healthcare systems. By synthesizing recent findings from clinical trials and studies, this review aims to inform healthcare professionals and policymakers about the evolving strategies in the fight against obesity, ultimately contributing to improved patient outcomes and reduced healthcare costs.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Current Pharmacological Treatments for Obesity
    • 2.1 Overview of Approved Medications
    • 2.2 Mechanisms of Action
    • 2.3 Efficacy and Safety Profiles
  • 3 Surgical Interventions
    • 3.1 Types of Bariatric Surgery
    • 3.2 Indications and Contraindications
    • 3.3 Long-term Outcomes and Risks
  • 4 Lifestyle Modifications and Behavioral Therapies
    • 4.1 Dietary Interventions
    • 4.2 Physical Activity Recommendations
    • 4.3 Psychological Support and Counseling
  • 5 Emerging Treatments and Future Directions
    • 5.1 Novel Pharmacological Agents
    • 5.2 Gene Therapy and Personalized Medicine
    • 5.3 Technology-Driven Solutions (e.g., Apps, Wearables)
  • 6 Public Health Implications
    • 6.1 Impact on Healthcare Systems
    • 6.2 Policy Recommendations
    • 6.3 Community-Based Approaches
  • 7 Conclusion

1 Introduction ​

Obesity has emerged as a critical global health challenge, with its prevalence increasing dramatically over the past few decades. Defined by the World Health Organization as a body mass index (BMI) of 30 or greater, obesity is associated with numerous comorbidities, including cardiovascular diseases, type 2 diabetes, and certain cancers, thereby significantly impacting healthcare systems and economies worldwide[1][2]. The complex nature of obesity, influenced by genetic, environmental, and behavioral factors, necessitates a multifaceted approach to treatment and management. Recent estimates indicate that nearly 650 million adults globally are classified as obese, a figure that underscores the urgent need for effective therapeutic strategies[3].

The significance of addressing obesity extends beyond individual health; it poses a substantial burden on public health resources, contributing to rising healthcare costs and reduced quality of life for affected individuals. Therefore, advancing our understanding of obesity treatment options is imperative for healthcare professionals and policymakers alike. While lifestyle modifications such as diet and exercise remain the cornerstone of obesity management, they often yield only modest results, highlighting the necessity for pharmacological and surgical interventions[4][5]. Over the past decade, there has been a paradigm shift in obesity treatment, with the development of new pharmacological agents and surgical techniques that have shown promising efficacy and safety profiles[2].

Current pharmacological treatments for obesity include a range of medications approved by the U.S. Food and Drug Administration (FDA), such as orlistat, liraglutide, and the more recently introduced semaglutide and tirzepatide[5]. These agents primarily target appetite regulation and metabolic processes, offering patients additional options when lifestyle changes alone are insufficient[6]. Surgical interventions, particularly bariatric surgery, continue to be regarded as the "gold standard" for weight loss in individuals with severe obesity, providing significant and sustained weight reduction along with improvements in metabolic health[1]. Furthermore, emerging treatments such as gene therapy and technology-driven solutions are beginning to reshape the landscape of obesity management, presenting novel avenues for personalized medicine[2].

This review will systematically explore the latest advancements in obesity treatment, structured as follows:

  1. Current Pharmacological Treatments for Obesity: This section will provide an overview of approved medications, detailing their mechanisms of action, efficacy, and safety profiles.

  2. Surgical Interventions: We will examine various types of bariatric surgery, indications and contraindications for these procedures, and long-term outcomes and risks associated with surgical weight loss interventions.

  3. Lifestyle Modifications and Behavioral Therapies: This part will discuss dietary interventions, physical activity recommendations, and the importance of psychological support and counseling in the context of obesity treatment.

  4. Emerging Treatments and Future Directions: We will highlight novel pharmacological agents, the potential of gene therapy, and technology-driven solutions such as mobile applications and wearable devices that may enhance obesity management.

  5. Public Health Implications: This section will address the impact of obesity treatments on healthcare systems, policy recommendations, and community-based approaches to tackle the obesity epidemic.

In conclusion, this report aims to synthesize recent findings from clinical trials and studies, providing a comprehensive overview of the efficacy, safety, and accessibility of the latest treatments for obesity. By equipping healthcare professionals and researchers with updated knowledge, we hope to inform clinical practice and policy-making in the ongoing fight against obesity. The insights gained from this review will be crucial for developing effective strategies to combat this pervasive public health issue.

2 Current Pharmacological Treatments for Obesity ​

2.1 Overview of Approved Medications ​

Obesity is recognized as a chronic, relapsing disease that necessitates comprehensive management strategies, including pharmacological interventions. As of 2023, there are several medications approved for the treatment of obesity, which have evolved significantly over the years. The following provides an overview of the current pharmacological treatments for obesity, highlighting the approved medications and their mechanisms of action.

Currently, five main pharmaceutical strategies are approved by the US Food and Drug Administration (FDA) for the treatment of obesity: orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion. Among these, the combination of phentermine/topiramate is considered the most effective, followed by lorcaserin and naltrexone/bupropion [3].

  1. Orlistat: This medication functions by inhibiting the enzyme lipase, thereby blocking fat digestion and absorption in the gastrointestinal tract. While it may not be as effective as other drugs in terms of weight loss, orlistat is currently the only choice available that has a favorable safety profile concerning cardiovascular events [7].

  2. Lorcaserin: Approved in 2012, lorcaserin acts as a selective serotonin 2C receptor agonist, promoting satiety and reducing appetite. It has shown efficacy in weight management and is associated with improvements in metabolic parameters [8].

  3. Liraglutide: Originally developed for the treatment of type 2 diabetes, liraglutide has been repurposed for obesity management at a higher dose (3.0 mg). It works by mimicking the effects of the hormone GLP-1, which enhances insulin secretion, inhibits glucagon release, and promotes satiety [6].

  4. Phentermine/Topiramate: This combination medication, approved for long-term use, combines the appetite suppressant phentermine with topiramate, which has weight loss effects. The combination enhances weight loss compared to either drug alone and is often utilized for patients with obesity [9].

  5. Naltrexone/Bupropion: This combination leverages the effects of naltrexone, an opioid antagonist, and bupropion, an antidepressant that also aids in weight loss. Together, they help reduce appetite and increase energy expenditure [10].

Emerging treatments include semaglutide and tirzepatide, which are also based on incretin hormones and have shown promise in clinical trials for their weight loss efficacy and improvements in metabolic health. These newer agents primarily act centrally to reduce appetite and increase satiety, with additional effects on gastrointestinal function, such as slowing gastric emptying [5].

In summary, the landscape of pharmacological treatments for obesity has expanded significantly, with several effective medications now available that not only facilitate weight loss but also improve associated comorbidities. The choice of medication should be tailored to the individual patient's clinical profile, considering factors such as comorbidities, safety profiles, and expected weight loss outcomes [11]. As research continues, new pharmacological options are likely to emerge, enhancing the management of obesity and its related health issues.

2.2 Mechanisms of Action ​

The management of obesity has seen significant advancements in recent years, particularly in pharmacological treatments that target various mechanisms of action. As of now, several medications have been approved by the US FDA for the treatment of obesity, including orlistat, lorcaserin, liraglutide, phentermine/topiramate, and bupropion/naltrexone. These agents work through different mechanisms to promote weight loss and improve metabolic health.

  1. Orlistat: This medication functions by inhibiting gastrointestinal lipase, which blocks the digestion and absorption of dietary fats in the intestines. By preventing fat absorption, orlistat can lead to weight loss, typically resulting in an additional weight loss of about 2-5 kg beyond what can be achieved through lifestyle changes alone [12].

  2. Phentermine/Topiramate: This combination therapy is noted for its effectiveness in appetite suppression and thermogenesis promotion. Phentermine acts as an appetite suppressant, while topiramate contributes to increased satiety and reduced food intake. This combination has shown substantial efficacy in clinical settings, making it one of the more effective treatments for obesity [3].

  3. Liraglutide and Semaglutide: Both are glucagon-like peptide-1 (GLP-1) receptor agonists that enhance glucose-dependent insulin secretion, suppress glucagon secretion, and slow gastric emptying. These actions not only lead to weight loss but also improve metabolic parameters such as lipid profiles and glucose levels. Semaglutide, in particular, has been highlighted for its significant weight loss results in clinical trials [5].

  4. Naltrexone/Bupropion: This combination targets the central nervous system to suppress appetite and enhance energy expenditure. Bupropion, an antidepressant, is thought to reduce cravings, while naltrexone, an opioid antagonist, may block pathways that stimulate hunger [3].

  5. Tirzepatide: Recently, this dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist has shown promise in clinical trials and is anticipated to receive FDA approval. It acts on both the central nervous system to reduce appetite and the gastrointestinal tract to slow gastric emptying, resulting in significant weight loss [5].

In addition to these medications, ongoing research is exploring new therapeutic agents that target additional mechanisms involved in energy homeostasis. These include potential drugs that act on pathways such as the melanocortin system, gut peptides, and other neurohormonal systems regulating appetite and metabolism [13].

The development of these pharmacological treatments represents a shift towards more individualized and effective strategies for managing obesity, acknowledging the complexity of weight regulation and the necessity for combination therapies to achieve sustained success [14]. The current landscape indicates a promising future for obesity management through both existing and emerging pharmacotherapies, which aim to not only reduce weight but also improve overall metabolic health [2].

2.3 Efficacy and Safety Profiles ​

Obesity remains a significant public health challenge, with a growing number of pharmacological treatments emerging to address this issue. As of 2023, several medications have been approved for the long-term management of obesity, reflecting advancements in the understanding of obesity's complex pathophysiology. The current pharmacological options include:

  1. Orlistat: This medication inhibits the absorption of dietary fats in the intestines, leading to reduced caloric intake. It has been a long-standing option for weight management but is limited by gastrointestinal side effects.

  2. Phentermine/Topiramate: This combination therapy has shown considerable efficacy, with studies indicating a weight loss of approximately 9% beyond lifestyle modifications. It acts as an appetite suppressant and promotes satiety, making it one of the more effective treatments available.

  3. Naltrexone/Bupropion: This combination works by affecting the central nervous system to reduce appetite and cravings. It has been associated with a weight loss of around 5% to 7% when combined with lifestyle changes.

  4. Liraglutide: Originally developed for diabetes management, this GLP-1 receptor agonist has been repurposed for obesity treatment. It promotes weight loss by enhancing satiety and slowing gastric emptying, resulting in an average weight reduction of about 6% to 8%.

  5. Semaglutide: A newer GLP-1 receptor agonist, semaglutide has shown significant weight loss results, with studies indicating an average reduction of 15% or more in body weight. It operates similarly to liraglutide but with a more potent effect.

  6. Tirzepatide: This medication, which is under investigation, is based on a dual action mechanism that targets both GLP-1 and GIP receptors, showing promising results in early trials for weight loss and metabolic improvements.

In terms of efficacy, the weight loss achieved with these medications varies, generally ranging from 3% to over 15% of body weight, depending on the specific drug and patient adherence to lifestyle modifications. The choice of medication should be tailored to individual patient profiles, considering factors such as comorbidities, potential side effects, and the expected degree of weight loss[3][5][10].

Regarding safety profiles, each medication comes with its own set of potential side effects. For instance, orlistat can lead to gastrointestinal issues, while phentermine/topiramate may raise concerns about cardiovascular effects. Naltrexone/bupropion has been linked to neuropsychiatric effects, and liraglutide and semaglutide may cause gastrointestinal disturbances. It is crucial for healthcare providers to weigh the benefits against these risks when prescribing these medications[5][6][15].

In summary, the pharmacological landscape for obesity treatment is evolving, with several effective options now available that target various mechanisms of appetite regulation and metabolic function. Ongoing research and clinical trials continue to explore new treatments and improve the safety and efficacy of existing ones, paving the way for more personalized approaches to obesity management[4][5].

3 Surgical Interventions ​

3.1 Types of Bariatric Surgery ​

Bariatric surgery has emerged as a prominent and effective treatment for severe obesity, particularly in patients with a body mass index (BMI) greater than 35 kg/m². The contemporary landscape of bariatric surgery encompasses a variety of surgical procedures that can be classified into two main categories: surgical and endoscopic interventions.

Surgical procedures include:

  1. Roux-en-Y Gastric Bypass (RYGB): This is one of the most commonly performed bariatric surgeries. It involves creating a small pouch from the stomach and connecting it directly to the small intestine, which results in reduced food intake and altered nutrient absorption.

  2. Sleeve Gastrectomy: This procedure involves the removal of a large portion of the stomach, leaving a tube-like structure. It is known for its simplicity and has become increasingly popular due to its favorable outcomes.

  3. Bilio-Pancreatic Diversion (BPD) with or without Duodenal Switch: This complex procedure involves both restriction and malabsorption. It is typically reserved for patients with severe obesity due to its higher risk profile.

  4. Stomach Intestinal Pylorus Sparing Surgery (SIPS): A newer approach that preserves the pylorus and modifies the gastrointestinal tract to promote weight loss.

Endoscopic procedures, which are less invasive than traditional surgical methods, include:

  1. Intragastric Balloons: These devices are placed in the stomach to promote a feeling of fullness, thus reducing food intake.

  2. Transpyloric Shuttle: This is an adjustable device that is placed in the stomach to control food passage into the intestine.

  3. Endoscopic Gastroplasties: Techniques that modify the stomach's size and shape through endoscopic methods.

  4. Aspiration Therapy: This involves the placement of a device that allows for the aspiration of food from the stomach after meals.

  5. Duodenal Mucosal Resurfacing: A procedure that aims to improve glucose metabolism by altering the mucosal surface of the duodenum.

  6. Duodeno-Jejunal Bypass Liner: A device that lines the small intestine to promote weight loss and improve metabolic outcomes.

  7. Incisionless Magnetic Anastomosis System: A newer technique that creates connections between the stomach and intestines without the need for incisions.

Despite the effectiveness of these interventions, challenges such as high costs, availability, and potential complications remain. For instance, weight regain is a common issue following surgery, necessitating revisional metabolic procedures in some cases. Additionally, a thorough pre-operative evaluation and post-surgery management of nutritional deficiencies are crucial for optimal outcomes.

Recent advancements in pharmacotherapy, particularly glucagon-like insulinotropic peptide-1 receptor agonists (GLP-1 RAs) and co-agonists like Tirzepatide, have shown promising weight loss potential comparable to surgical interventions. These developments raise questions about their role in potentially reducing the need for invasive surgical procedures in the future.

The choice of the most appropriate bariatric procedure is highly individualized, taking into account factors such as the desired magnitude of weight loss, comorbidities, surgical fitness, and patient preference. The comprehensive understanding of these options enables clinicians to tailor interventions to meet the specific needs of patients, including those in special populations such as the elderly and pediatric age groups, as well as individuals with type 1 diabetes and non-diabetics [16][17][18].

3.2 Indications and Contraindications ​

The treatment of obesity has evolved significantly, with surgical interventions being recognized as a primary method for achieving substantial and sustained weight loss, particularly in patients with severe obesity. The most current and effective surgical options include Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding, and duodenal switch. Each of these procedures is designed to promote weight loss through mechanisms of restriction and/or malabsorption, with the majority being performed laparoscopically, which enhances recovery times and minimizes complications compared to open surgery [17].

Indications for bariatric surgery typically include a body mass index (BMI) of 40 kg/m² or greater, or a BMI of 35 kg/m² or greater accompanied by obesity-related comorbidities such as type 2 diabetes mellitus, hypertension, or obstructive sleep apnea [19]. The goal of these interventions is not only to achieve significant weight loss but also to ameliorate associated metabolic disorders, thereby improving overall health and quality of life [17].

Contraindications for bariatric surgery generally encompass a range of factors that may increase surgical risk or reduce the likelihood of successful outcomes. These include uncontrolled psychiatric disorders, severe substance abuse, and certain medical conditions that could complicate the surgery or recovery [19]. Furthermore, patients who are not committed to lifestyle changes post-surgery may also be deemed unsuitable candidates, as long-term success relies heavily on adherence to dietary and exercise regimens following the procedure [20].

In addition to traditional surgical methods, there is a growing interest in less invasive endoscopic techniques that mimic bariatric surgery's effects. These procedures are designed for patients who may not qualify for traditional surgery due to lower BMI or other factors. Such techniques include gastric balloons, gastric plication, and various forms of gastric nerve stimulation [21]. These interventions aim to provide a safer, reversible, and cost-effective alternative for managing obesity, thus expanding the treatment options available for individuals struggling with weight control [22].

In summary, the landscape of obesity treatment is shifting towards a combination of surgical and minimally invasive interventions, each tailored to individual patient needs and conditions. Ongoing research continues to refine these approaches, aiming to enhance safety, efficacy, and accessibility for a broader range of patients suffering from obesity and its related health complications [1].

3.3 Long-term Outcomes and Risks ​

Obesity is a significant public health issue that is associated with numerous comorbidities, including type 2 diabetes, cardiovascular disease, and hypertension. Surgical interventions, particularly bariatric surgery, have emerged as the most effective long-term treatment options for severe obesity, defined as a body mass index (BMI) of 35 kg/m² or greater. These surgical procedures include Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding, among others. Each of these methods aims to induce significant weight loss through mechanisms such as gastric restriction or malabsorption, leading to improvements in obesity-related comorbidities and overall mortality rates[21].

Long-term outcomes following bariatric surgery are generally favorable. Studies indicate that metabolic surgery results in substantial and sustained weight loss, with many patients experiencing improvements in their comorbid conditions, including type 2 diabetes and cardiovascular disease[23]. The efficacy of these surgical interventions is supported by evidence showing that even modest weight loss can significantly ameliorate diabetes and cardiovascular risk factors[24].

However, bariatric surgery is not without risks. Potential complications can occur both in the short term and long term. Short-term risks include infections, bleeding, and complications related to anesthesia, while long-term risks may involve nutritional deficiencies, gastrointestinal complications, and the need for additional surgeries[19]. Furthermore, the high upfront costs associated with surgical procedures can limit their accessibility and scalability in the general population, necessitating careful consideration of individual patient needs and health status[23].

In light of these factors, the decision to pursue surgical intervention must be made collaboratively between the patient and healthcare provider, taking into account the severity of obesity, presence of comorbidities, and the patient’s preferences[23]. Future research aims to enhance the understanding of obesity pathophysiology and improve the safety and effectiveness of both surgical and nonsurgical treatment options, thereby expanding the range of therapeutic strategies available for managing obesity and its associated health risks[19].

In summary, while bariatric surgery remains the gold standard for treating severe obesity and its comorbidities, ongoing developments in medical therapies and minimally invasive techniques are also being explored to provide additional options for patients, particularly those who may not be candidates for surgery[1].

4 Lifestyle Modifications and Behavioral Therapies ​

4.1 Dietary Interventions ​

Recent literature highlights that lifestyle modifications, particularly dietary interventions, remain foundational in the management of obesity. These interventions are integral to a comprehensive treatment strategy that also includes physical activity and behavioral therapies.

A review by Khani et al. (2025) emphasizes that effective dietary interventions, along with behavioral therapies and pharmacological agents, are crucial in addressing obesity within primary care settings. The study notes that comprehensive lifestyle modifications can lead to significant weight loss, thereby reducing the risk of obesity-related comorbidities such as diabetes and cardiovascular diseases[25].

In terms of specific dietary strategies, Vetter et al. (2010) indicate that a comprehensive program that combines dietary changes, increased physical activity, and behavior therapy can result in a mean weight loss of 7-10% of initial body weight. This magnitude of weight loss has been shown to substantially decrease the risk of developing type 2 diabetes in individuals with impaired glucose tolerance[26]. Furthermore, the American Gastroenterological Association's guidelines from 2022 recommend integrating pharmacologic agents with lifestyle interventions for adults who do not achieve sufficient results from dietary and exercise changes alone[27].

Moreover, the review by Mehta et al. (2021) discusses various dietary interventions and the importance of personalizing these strategies to meet individual patient needs. This multifaceted approach not only includes traditional dietary changes but also leverages newer technologies to enhance engagement and adherence to dietary plans[28].

Chao et al. (2025) further elaborate on the importance of behavioral treatment, which often includes dietary counseling as a core component. The review indicates that behavioral interventions can induce average weight reductions of 5-10% over six to twelve months, which is significant for improving health outcomes and reducing healthcare costs associated with obesity[29].

In conclusion, the latest treatments for obesity underscore the critical role of dietary interventions within a broader framework of lifestyle modifications and behavioral therapies. The integration of these strategies, alongside emerging pharmacological treatments, represents a comprehensive approach to managing obesity effectively. Continued research and innovation in this area are essential to enhance the efficacy and accessibility of obesity treatments.

4.2 Physical Activity Recommendations ​

The management of obesity has evolved significantly, particularly in the context of lifestyle modifications and behavioral therapies. Current recommendations emphasize a comprehensive approach that integrates diet, physical activity, and behavior therapy to achieve sustainable weight loss.

A structured lifestyle modification program typically involves a combination of dietary changes, increased physical activity, and behavioral therapy. Such programs can induce a mean weight loss of 7-10% of initial body weight in individuals with obesity, which is associated with substantial health benefits, including a reduced risk of developing type 2 diabetes mellitus in those with impaired glucose tolerance [26]. Additionally, lifestyle interventions remain the foundation for managing obesity, even as pharmacologic therapies have emerged as adjunctive treatments [2].

Physical activity is a critical component of obesity management. The American Gastroenterological Association has recommended that adults with obesity or overweight, particularly those with weight-related complications, should incorporate increased physical activity into their lifestyle interventions [27]. The current guidelines suggest that adults engage in at least 150 minutes of moderate-intensity aerobic activity each week, along with muscle-strengthening activities on two or more days a week [1]. These recommendations aim to enhance overall physical fitness, improve metabolic health, and facilitate weight management.

Behavioral therapies are essential for supporting individuals in making and sustaining lifestyle changes. These therapies often include techniques such as goal setting, self-monitoring, problem-solving, and reinforcement strategies to encourage adherence to diet and exercise regimens [30]. Recent advancements in technology have also opened new avenues for delivering behavioral interventions, utilizing mobile applications and online platforms to increase accessibility and engagement [30].

In summary, the latest treatments for obesity underscore the importance of lifestyle modifications, particularly dietary changes and physical activity, complemented by behavioral therapies. These strategies are foundational in promoting weight loss and improving health outcomes for individuals struggling with obesity.

4.3 Psychological Support and Counseling ​

Obesity is recognized as a complex, multifactorial disorder that poses significant health risks, including diabetes and cardiovascular diseases. The management of obesity typically begins with lifestyle modifications, which include dietary changes, increased physical activity, and behavioral therapies. Recent literature emphasizes the importance of psychological support and counseling as integral components of these lifestyle modifications.

Lifestyle interventions remain the cornerstone of obesity management. A comprehensive program that includes dietary adjustments, physical activity, and behavior therapy has been shown to induce a mean weight loss of 7-10% of initial body weight within six to twelve months. This level of weight loss is associated with significant health benefits, such as reduced risk of developing type 2 diabetes and improved cardiovascular health[26]. Behavioral therapies often encompass techniques such as goal setting, self-monitoring, and problem-solving strategies, which are essential for fostering lasting changes in eating and activity habits[30].

Psychological support and counseling play a crucial role in addressing the behavioral aspects of obesity treatment. Cognitive-behavioral therapy (CBT) and motivational interviewing are two evidence-based approaches that have been effective in helping individuals overcome barriers to weight loss and maintain long-term lifestyle changes[25]. The integration of psychological support into treatment plans not only enhances adherence to lifestyle changes but also addresses emotional and psychological factors that contribute to obesity.

Moreover, recent advancements in technology have facilitated the delivery of behavioral interventions through digital platforms, such as mobile applications and online counseling, which can increase engagement and accessibility for patients[30]. These innovative methods allow for real-time self-monitoring and feedback, which are critical for sustaining behavior change.

While lifestyle modifications and behavioral therapies form the foundation of obesity management, pharmacologic treatments are increasingly being recognized as valuable adjuncts for patients who do not achieve sufficient weight loss through lifestyle changes alone. New pharmacological agents, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have emerged as effective options that can lead to significant weight loss and improvement in metabolic parameters[2].

In conclusion, the latest treatments for obesity underscore the importance of a multifaceted approach that includes lifestyle modifications, behavioral therapies, and psychological support. This comprehensive strategy aims not only to achieve weight loss but also to promote long-term health and well-being in individuals struggling with obesity. Future research should continue to explore the efficacy of these interventions and their integration into personalized treatment plans for optimal outcomes.

5 Emerging Treatments and Future Directions ​

5.1 Novel Pharmacological Agents ​

The treatment landscape for obesity is evolving rapidly, with significant advancements in pharmacotherapy aimed at addressing this global epidemic. As of 2023, several medications have been approved for the long-term management of obesity, with a focus on innovative mechanisms of action that enhance efficacy and minimize side effects.

Currently, the US Food and Drug Administration (FDA) has approved five primary medications for non-syndromic obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, and semaglutide. These agents are designed to facilitate weight loss through various pathways, including appetite suppression and increased satiety. For instance, semaglutide, which acts as a GLP-1 receptor agonist, has shown considerable promise in clinical trials, leading to significant weight loss and improvements in metabolic parameters[5].

In addition to these established treatments, there are emerging pharmacological agents currently under investigation. Tirzepatide, a dual GLP-1 and GIP receptor agonist, is gaining attention for its potential to provide substantial weight loss results, with studies indicating that it may outperform existing therapies[5]. Other novel agents are being developed that target different aspects of appetite regulation and energy expenditure, reflecting a shift towards more personalized approaches in obesity treatment[5].

Moreover, the landscape of obesity pharmacotherapy is not only expanding in terms of new medications but also through the development of combination therapies. The understanding that obesity is a complex, multifactorial disease necessitates a combination of treatments that may include pharmacotherapy, lifestyle modifications, and possibly surgical interventions[6]. As research progresses, the integration of pharmacogenetic and nutrigenetic approaches into obesity management is also anticipated, allowing for tailored treatments based on individual genetic profiles[3].

In summary, the latest treatments for obesity encompass a range of approved medications and novel pharmacological agents currently under investigation. These developments reflect a growing recognition of obesity as a chronic disease that requires a comprehensive, multidisciplinary approach to management. The future of obesity treatment is poised to leverage advanced therapeutic strategies that combine pharmacotherapy with personalized medicine, ultimately aiming to improve outcomes for individuals struggling with obesity.

5.2 Gene Therapy and Personalized Medicine ​

Recent advancements in obesity treatment have emphasized the importance of personalized medicine and the exploration of innovative therapeutic strategies, including gene therapy. The obesity epidemic continues to be a pressing public health challenge, necessitating the development of more effective treatment modalities beyond traditional lifestyle interventions and pharmacotherapy.

In the realm of pharmacotherapy, there has been a notable increase in the approval of new agents that target various physiological mechanisms involved in weight regulation. For instance, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have emerged as powerful tools for weight management, leading to significant reductions in body weight and improvements in metabolic parameters, including glucose levels and lipid profiles [2]. These agents not only enhance satiety but also modify appetite regulation pathways, offering a multifaceted approach to obesity management.

Furthermore, the landscape of obesity pharmacotherapy is rapidly evolving, with ongoing research into novel compounds that may target additional pathways. The combination of existing medications is also being explored to enhance efficacy and reduce side effects. For example, the dual GLP-1/GIP receptor agonists have shown promise in clinical trials, potentially offering even greater weight loss benefits [31].

In addition to pharmacological advancements, gene therapy is gaining traction as a potential avenue for treating obesity. The understanding of genetic factors influencing obesity is crucial, as individual genetic profiles can significantly affect treatment responses. Recent studies suggest that pharmacogenetic approaches—tailoring drug therapies based on an individual’s genetic makeup—could optimize treatment outcomes and minimize adverse effects [3].

Moreover, the integration of artificial intelligence in obesity management is being investigated, with the potential to personalize treatment plans based on patient data, including genetic, behavioral, and clinical characteristics [31]. This approach aims to refine treatment strategies, allowing for more precise targeting of therapies that align with individual patient needs.

While gene therapy remains largely in the research phase, the potential to manipulate genes associated with appetite regulation and energy metabolism could revolutionize obesity treatment in the future. This could involve the development of molecular vaccines targeting hormones like ghrelin and GIP, which play crucial roles in energy homeostasis [32].

In conclusion, the latest treatments for obesity are characterized by a shift towards personalized medicine, incorporating advanced pharmacotherapies and innovative strategies such as gene therapy. The ongoing exploration of genetic influences and the integration of technology into treatment paradigms are poised to shape the future of obesity management, ultimately aiming for more effective and individualized care. As research continues to evolve, it is essential to monitor these developments closely to harness their full potential in combating obesity and its associated comorbidities.

5.3 Technology-Driven Solutions (e.g., Apps, Wearables) ​

The treatment landscape for obesity is evolving rapidly, particularly with the integration of technology-driven solutions. Recent literature highlights various innovative approaches, emphasizing the role of digital health technologies such as mobile applications, wearable devices, and telemedicine in managing obesity.

Mobile health applications have emerged as a significant tool in obesity management. They facilitate self-monitoring of dietary intake and physical activity, which can lead to behavioral changes and weight loss. A systematic review by Rumbo-Rodríguez et al. (2020) found that approximately 47% of technology-based interventions resulted in significant weight loss in obese patients, underscoring the effectiveness of these digital tools[33]. Additionally, the automated feedback provided by smartphone applications has been shown to effectively manage conditions like type 2 diabetes, while also encouraging lifestyle changes necessary for obesity management[34].

Wearable devices, including activity trackers, also play a crucial role in this landscape. However, the effectiveness of these devices can vary. Price et al. (2022) noted that while smartphone applications requiring patient interaction were more effective at engaging users, passive devices like activity trackers were less successful in prompting the necessary lifestyle changes[34]. The integration of automated digital health solutions is particularly relevant in the context of social isolation exacerbated by the COVID-19 pandemic, which has highlighted the potential for these technologies to provide accessible care during challenging times[34].

Telemedicine has gained prominence as an effective modality for obesity treatment, especially for patients who prefer remote consultations. Research indicates that telemedicine can facilitate self-management skills and enhance adherence to behavioral interventions[35]. The flexibility of telehealth services allows for personalized care, which is essential in addressing the unique challenges faced by individuals with obesity.

Moreover, advancements in artificial intelligence (AI) and machine learning are paving the way for increasingly personalized and automated interventions. Future applications of these technologies could lead to more tailored weight management strategies, enhancing both the effectiveness and accessibility of obesity treatments[36].

In summary, the latest treatments for obesity are increasingly characterized by the use of technology-driven solutions, including mobile health applications, wearable devices, and telemedicine. These innovations not only improve access to care but also enhance patient engagement and support long-term weight management strategies. The ongoing development and integration of these technologies into clinical practice will be critical in addressing the obesity epidemic effectively.

6 Public Health Implications ​

6.1 Impact on Healthcare Systems ​

Obesity is a growing epidemic with significant implications for public health and healthcare systems globally. The prevalence of obesity has nearly doubled in less than 35 years, leading to increased rates of associated comorbidities such as type 2 diabetes, cardiovascular disease, and various psychosocial issues. This escalating health crisis places considerable strain on healthcare resources and necessitates effective treatment strategies to manage obesity and its complications.

Recent advancements in obesity treatment have expanded the pharmacotherapeutic landscape significantly. Currently, five medications are approved by the US Food and Drug Administration (FDA) for chronic weight management in obese adults: orlistat, lorcaserin, liraglutide, phentermine/topiramate, and bupropion/naltrexone. These drugs have demonstrated varying degrees of efficacy, with weight loss ranging from approximately 3% to 9% beyond lifestyle modifications after one year of treatment (Gadde & Raj 2017). Notably, the combined administration of phentermine/topiramate appears to be the most effective, followed by lorcaserin and bupropion/naltrexone (Solas et al. 2016).

In addition to traditional pharmacotherapy, newer treatment modalities are emerging, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide, which have shown significant efficacy in promoting weight loss and improving metabolic parameters (Roomy et al. 2024). The recently approved dual GLP-1/GIP receptor agonist tirzepatide is also making strides in obesity management, indicating a promising future for peptide-based therapies in this field.

Bariatric surgery remains the "gold standard" for obesity treatment, particularly for patients with severe obesity or those who have not responded to pharmacotherapy. Surgical options such as Roux-en-Y gastric bypass and sleeve gastrectomy have demonstrated superior efficacy in achieving weight reduction and metabolic improvements, albeit with potential complications (Vairavamurthy et al. 2017).

Moreover, ongoing research is exploring innovative approaches to obesity treatment, including the use of biomaterials for targeted drug delivery, nanomedicine, and the development of obesity vaccines. These strategies aim to enhance therapeutic efficiency while minimizing adverse effects, addressing some of the limitations associated with current pharmacological treatments (Li et al. 2022; Zhang et al. 2018; Monteiro 2014).

The implications of these treatment advancements for public health are profound. Effective obesity management not only reduces the burden of related diseases but also alleviates pressure on healthcare systems. By improving weight management strategies, healthcare providers can enhance patient outcomes, reduce healthcare costs, and ultimately improve the quality of life for individuals affected by obesity.

In conclusion, the landscape of obesity treatment is evolving, with a focus on pharmacotherapy, surgical interventions, and innovative therapeutic strategies. As these treatments continue to develop, their integration into public health initiatives will be crucial for addressing the obesity epidemic and its extensive impact on healthcare systems.

6.2 Policy Recommendations ​

Obesity has emerged as a significant global health crisis, necessitating innovative therapeutic approaches to manage this complex condition effectively. Recent advancements in obesity treatments have highlighted a range of pharmacological interventions, lifestyle modifications, and surgical options, each with distinct implications for public health and policy.

Pharmacological treatments have evolved considerably in recent years. Currently, the U.S. Food and Drug Administration (FDA) has approved several medications for long-term obesity management, including orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, and the recently approved semaglutide and tirzepatide [5]. These agents operate through various mechanisms, primarily targeting appetite regulation and satiety enhancement. For instance, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide have demonstrated significant efficacy in promoting weight loss and improving metabolic parameters [2]. Moreover, newer medications are under investigation, focusing on novel mechanisms of action, particularly those that act on incretin pathways [5].

Bariatric surgery remains a cornerstone of obesity treatment, particularly for individuals with severe obesity or those who have not responded to pharmacotherapy. Procedures such as Roux-en-Y gastric bypass and sleeve gastrectomy are associated with substantial weight loss and improvements in obesity-related comorbidities [1]. However, surgical interventions carry risks of complications, which necessitates careful patient selection and counseling [1].

Lifestyle interventions, including diet and exercise, continue to be foundational in obesity management. Despite their importance, many patients struggle to achieve and maintain weight loss through these methods alone [32]. Consequently, pharmacotherapy is often considered a necessary adjunct to lifestyle changes, particularly for individuals who find sustained behavioral modifications challenging [32].

From a public health perspective, the rise in obesity prevalence has profound implications for healthcare systems, increasing the burden of related comorbidities such as type 2 diabetes, cardiovascular diseases, and certain cancers [3]. Therefore, it is crucial for policymakers to advocate for comprehensive obesity management strategies that encompass not only pharmacological and surgical options but also community-based interventions aimed at promoting healthy lifestyles [4].

Policy recommendations should focus on enhancing access to effective obesity treatments, including insurance coverage for pharmacotherapy and surgical options, to reduce the economic burden on individuals and healthcare systems. Furthermore, public health campaigns should aim to raise awareness about the multifaceted nature of obesity, emphasizing that it is a chronic disease requiring ongoing management rather than a simple lifestyle failure [4].

In conclusion, the latest treatments for obesity encompass a spectrum of pharmacological, surgical, and lifestyle interventions. As the understanding of obesity as a complex, multifactorial disease evolves, so too must the policies that govern its management, ensuring that effective, evidence-based strategies are accessible to all individuals affected by this growing epidemic.

6.3 Community-Based Approaches ​

Obesity has emerged as a global epidemic, presenting significant public health challenges due to its association with various comorbidities, including cardiovascular disease, type 2 diabetes, and metabolic disorders. The treatment landscape for obesity has evolved considerably, incorporating pharmacotherapy, lifestyle modifications, and surgical interventions.

Currently, the U.S. Food and Drug Administration (FDA) has approved several pharmacological treatments for chronic weight management in obese adults. These include orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide [3][6]. These medications demonstrate varying degrees of efficacy, with weight loss outcomes ranging from approximately 3% to 9% over a year, depending on the drug and individual patient response [6]. Recent advances have introduced glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, which have shown significant efficacy in promoting weight loss and improving metabolic parameters [2].

In addition to pharmacotherapy, bariatric surgery remains a critical intervention for obesity, particularly for patients with severe obesity or those who have not responded adequately to other treatments. Surgical options include Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding, which have been shown to provide substantial and sustained weight loss along with improvements in obesity-related comorbidities [1].

Community-based approaches are increasingly recognized as vital components of obesity management. These approaches often focus on promoting lifestyle modifications, such as diet and physical activity, within community settings to facilitate behavior change and support weight management [24]. Programs may involve collaborations with local health organizations, schools, and community centers to create environments conducive to healthy living. Such initiatives can include access to healthy foods, opportunities for physical activity, and education on nutrition and health.

Moreover, there is a growing interest in innovative therapeutic strategies, including the development of biomaterial-based treatments and obesity vaccines targeting specific hormones involved in appetite regulation [32][37]. These emerging therapies aim to enhance treatment efficacy while minimizing side effects, addressing the limitations of current pharmacological options, which often suffer from poor bioavailability and target specificity [37].

The integration of personalized medicine, considering genetic and phenotypic differences among individuals, is also gaining traction in obesity management. This approach may lead to tailored treatments that optimize weight loss outcomes and reduce adverse effects [3].

In summary, the latest treatments for obesity encompass a multifaceted approach, integrating pharmacotherapy, surgical options, and community-based interventions aimed at promoting sustainable lifestyle changes. As the understanding of obesity continues to evolve, ongoing research and innovation in treatment strategies will be crucial to effectively combat this public health crisis.

7 Conclusion ​

The management of obesity has reached a critical juncture, marked by significant advancements in both pharmacological and surgical treatments. Current pharmacological options have expanded beyond traditional agents to include newer medications such as semaglutide and tirzepatide, which demonstrate superior efficacy in weight loss and metabolic improvement. Surgical interventions, particularly bariatric surgery, remain the gold standard for patients with severe obesity, yielding substantial long-term benefits. Furthermore, lifestyle modifications, including dietary changes and increased physical activity, are essential components of comprehensive obesity management. The integration of psychological support and technology-driven solutions, such as mobile applications and telehealth, has enhanced patient engagement and adherence to treatment plans. However, challenges remain, including access to care, the need for individualized treatment approaches, and addressing the social determinants of health. Future research should focus on innovative therapies, including gene therapy and personalized medicine, to further enhance treatment efficacy. As we move forward, it is imperative that healthcare systems and policymakers prioritize comprehensive, multifaceted strategies to combat the obesity epidemic and improve public health outcomes.

References ​

  • [1] Jenanan Vairavamurthy;Lawrence J Cheskin;Dara L Kraitchman;Aravind Arepally;Clifford R Weiss. Current and cutting-edge interventions for the treatment of obese patients.. European journal of radiology(IF=3.3). 2017. PMID:28668407. DOI: 10.1016/j.ejrad.2017.05.019.
  • [2] Moody Al Roomy;Kainat Hussain;Hawraa M Behbehani;Jenna Abu-Farha;Rayan Al-Harris;Aishwarya Mariam Ambi;Mohammed Altigani Abdalla;Fahd Al-Mulla;Mohamed Abu-Farha;Jehad Abubaker. Therapeutic advances in obesity management: an overview of the therapeutic interventions.. Frontiers in endocrinology(IF=4.6). 2024. PMID:38715796. DOI: 10.3389/fendo.2024.1364503.
  • [3] Maite Solas;Fermin I Milagro;Diego Martínez-Urbistondo;Maria J Ramirez;J Alfredo Martínez. Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches.. Trends in pharmacological sciences(IF=19.9). 2016. PMID:27236593. DOI: 10.1016/j.tips.2016.04.008.
  • [4] Ziad Omran. Obesity: Current Treatment and Future Horizons.. Mini reviews in medicinal chemistry(IF=3.3). 2017. PMID:27320641. DOI: 10.2174/1389557516666160617100328.
  • [5] Marlene Chakhtoura;Rachelle Haber;Malak Ghezzawi;Caline Rhayem;Raya Tcheroyan;Christos S Mantzoros. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.. EClinicalMedicine(IF=10.0). 2023. PMID:36992862. DOI: 10.1016/j.eclinm.2023.101882.
  • [6] Kishore M Gadde;Y Pritham Raj. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.. Current diabetes reports(IF=6.4). 2017. PMID:28378293. DOI: 10.1007/s11892-017-0859-2.
  • [7] Jun Goo Kang;Cheol-Young Park. Anti-Obesity Drugs: A Review about Their Effects and Safety.. Diabetes & metabolism journal(IF=8.5). 2012. PMID:22363917. DOI: 10.4093/dmj.2012.36.1.13.
  • [8] Donna H Ryan;George A Bray. Pharmacologic treatment options for obesity: what is old is new again.. Current hypertension reports(IF=5.1). 2013. PMID:23625271. DOI: 10.1007/s11906-013-0343-6.
  • [9] Katherine H Saunders;Rekha B Kumar;Leon I Igel;Louis J Aronne. Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.. Current atherosclerosis reports(IF=5.2). 2016. PMID:27181165. DOI: 10.1007/s11883-016-0589-y.
  • [10] K Fujioka. Current and emerging medications for overweight or obesity in people with comorbidities.. Diabetes, obesity & metabolism(IF=5.7). 2015. PMID:26040215. DOI: 10.1111/dom.12502.
  • [11] Amanda Velazquez;Caroline M Apovian. Updates on obesity pharmacotherapy.. Annals of the New York Academy of Sciences(IF=4.8). 2018. PMID:29377198. DOI: 10.1111/nyas.13542.
  • [12] David C Klonoff;Frank Greenway. Drugs in the pipeline for the obesity market.. Journal of diabetes science and technology(IF=3.7). 2008. PMID:19885278. DOI: 10.1177/193229680800200525.
  • [13] A G Powell;C M Apovian;L J Aronne. New drug targets for the treatment of obesity.. Clinical pharmacology and therapeutics(IF=5.5). 2011. PMID:21654742. DOI: 10.1038/clpt.2011.82.
  • [14] Dunstan Cooke;Steve Bloom. The obesity pipeline: current strategies in the development of anti-obesity drugs.. Nature reviews. Drug discovery(IF=101.8). 2006. PMID:17080028. DOI: 10.1038/nrd2136.
  • [15] Ashish Kumar Kakkar;Neha Dahiya. Drug treatment of obesity: current status and future prospects.. European journal of internal medicine(IF=6.1). 2015. PMID:25634851. DOI: .
  • [16] Sunetra Mondal;Vanessa Ambrose Fistus;Joseph M Pappachan. Bariatric and endo-bariatric interventions for diabetes: What is the current evidence?. World journal of diabetes(IF=4.6). 2024. PMID:39582566. DOI: 10.4239/wjd.v15.i11.2255.
  • [17] Ninh T Nguyen;J Esteban Varela. Bariatric surgery for obesity and metabolic disorders: state of the art.. Nature reviews. Gastroenterology & hepatology(IF=51.0). 2017. PMID:27899816. DOI: 10.1038/nrgastro.2016.170.
  • [18] Wei-Jei Lee;Owaid Almalki. Recent advancements in bariatric/metabolic surgery.. Annals of gastroenterological surgery(IF=3.3). 2017. PMID:29863165. DOI: 10.1002/ags3.12030.
  • [19] Talat Waseem;Kris M Mogensen;David B Lautz;Malcolm K Robinson. Pathophysiology of obesity: why surgery remains the most effective treatment.. Obesity surgery(IF=3.1). 2007. PMID:18000735. DOI: 10.1007/s11695-007-9220-1.
  • [20] Mathias A L Fobi;Hoil Lee;Basil Felahy;Kekah Che;Peter Ako;Nicole Fobi. Choosing an operation for weight control, and the transected banded gastric bypass.. Obesity surgery(IF=3.1). 2005. PMID:15760509. DOI: 10.1381/0960892052993404.
  • [21] Froukje J Verdam;Ruben Schouten;Jan Willem Greve;Ger H Koek;Nicole D Bouvy. An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery.. Journal of obesity(IF=3.9). 2012. PMID:22957215. DOI: 10.1155/2012/597871.
  • [22] Benjamin Charles Norton;Andrea Telese;Apostolis Papaefthymiou;Nasar Aslam;Janine Makaronidis;Charles Murray;Rehan Haidry. Metabolic and Bariatric Endoscopy: A Mini-Review.. Life (Basel, Switzerland)(IF=3.4). 2023. PMID:37763308. DOI: 10.3390/life13091905.
  • [23] Philip R Schauer;Amy E Rothberg. Point-Counterpoint Debate: Surgery vs Medical Treatment for the Management of Obesity.. The Journal of clinical endocrinology and metabolism(IF=5.1). 2025. PMID:39693237. DOI: 10.1210/clinem/dgae888.
  • [24] Ankur Jindal;Adam Whaley-Connell;Stephen Brietzke;James R Sowers. Therapy of obese patients with cardiovascular disease.. Current opinion in pharmacology(IF=4.2). 2013. PMID:23332347. DOI: .
  • [25] Mahan Khani;Reza Afsahi;Ali Ebrahimi Nasab;Sina Hemmati Bi'aragh;Kimia Rasouli;Mehdi Hassani Ahangar;Abbas Sarvari Soltani;Ramtin Pourahmad. Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies.. Diabetology & metabolic syndrome(IF=3.9). 2025. PMID:40846976. DOI: 10.1186/s13098-025-01925-z.
  • [26] Marion L Vetter;Lucy F Faulconbridge;Victoria L Webb;Thomas A Wadden. Behavioral and pharmacologic therapies for obesity.. Nature reviews. Endocrinology(IF=40.0). 2010. PMID:20680034. DOI: 10.1038/nrendo.2010.121.
  • [27] Risa B Burns;Melanie R Jay;Anne N Thorndike;Zahir Kanjee. How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.. Annals of internal medicine(IF=15.2). 2024. PMID:39374523. DOI: 10.7326/ANNALS-24-01740.
  • [28] Meetal Mehta;Nawfal W Istfan;Caroline M Apovian. Obesity: Overview of Weight Management.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists(IF=4.6). 2021. PMID:33901648. DOI: 10.1016/j.eprac.2021.04.001.
  • [29] Ariana M Chao;Molly Moore;Thomas A Wadden. The past, present, and future of behavioral obesity treatment.. International journal of obesity (2005)(IF=3.8). 2025. PMID:38678143. DOI: 10.1038/s41366-024-01525-3.
  • [30] Daniel E Okorodudu;Hayden B Bosworth;Leonor Corsino. Innovative interventions to promote behavioral change in overweight or obese individuals: A review of the literature.. Annals of medicine(IF=4.3). 2015. PMID:25011006. DOI: 10.3109/07853890.2014.931102.
  • [31] Abdullah Al Lawati;Ayman Alhabsi;Rhieya Rahul;Maria-Luisa Savino;Hamed Alwahaibi;Srijit Das;Hanan Al Lawati. Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.. Diseases (Basel, Switzerland)(IF=3.0). 2025. PMID:40422561. DOI: 10.3390/diseases13050129.
  • [32] Mariana P Monteiro. Obesity vaccines.. Human vaccines & immunotherapeutics(IF=3.5). 2014. PMID:24365968. DOI: .
  • [33] Lorena Rumbo-Rodríguez;Miriam Sánchez-SanSegundo;Nicolás Ruiz-Robledillo;Natalia Albaladejo-Blázquez;Rosario Ferrer-Cascales;Ana Zaragoza-Martí. Use of Technology-Based Interventions in the Treatment of Patients with Overweight and Obesity: A Systematic Review.. Nutrients(IF=5.0). 2020. PMID:33255982. DOI: 10.3390/nu12123634.
  • [34] James Christopher Price;Heitor Oliveira Santos;Allain Amador Bueno. The effectiveness of automated digital health solutions at successfully managing obesity and obesity-associated disorders: A PICO-structured investigation.. Digital health(IF=3.3). 2022. PMID:35401996. DOI: 10.1177/20552076221091351.
  • [35] Gretchen E Ames;Afton M Koball;Karen Grothe. Can Mobile Health Applications, Social Media, and Telemedicine Assist with Obesity Treatment?. Current obesity reports(IF=11.0). 2025. PMID:40531274. DOI: 10.1007/s13679-025-00647-7.
  • [36] Nigel Hinchliffe;Matthew S Capehorn;Michael Bewick;John Feenie. The Potential Role of Digital Health in Obesity Care.. Advances in therapy(IF=4.0). 2022. PMID:35925469. DOI: 10.1007/s12325-022-02265-4.
  • [37] Jing Li;Hongli Duan;Yan Liu;Lu Wang;Xing Zhou. Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities.. Pharmaceutics(IF=5.5). 2022. PMID:35890340. DOI: 10.3390/pharmaceutics14071445.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Obesity · Treatment · Pharmacological Interventions · Surgical Options · Lifestyle Modifications

© 2025 MaltSci